Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
309
-
Total 13F shares, excl. options
-
87.5M
-
Shares change
-
+1.23M
-
Total reported value, excl. options
-
$3.68B
-
Value change
-
+$41.5M
-
Put/Call ratio
-
1.27
-
Number of buys
-
146
-
Number of sells
-
-149
-
Price
-
$42.07
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2024
375 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2024.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 309 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.5M shares
of 96M outstanding shares and own 91.18% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (10M shares), BlackRock, Inc. (6.54M shares), SANDS CAPITAL MANAGEMENT, LLC (4.3M shares), STATE STREET CORP (2.72M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.51M shares), WELLINGTON MANAGEMENT GROUP LLP (2.46M shares), Clearbridge Investments, LLC (2.32M shares), FEDERATED HERMES, INC. (2.05M shares), RTW INVESTMENTS, LP (1.97M shares), and Rock Springs Capital Management LP (1.74M shares).
This table shows the top 309 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.